On Monday, the Seventh Circuit Court of Appeals issued an opinion in the case brought by Gripum, LLC against the U.S. Food and Drug Administration (FDA). The opinion, authored by Judges Wood, Hamilton, and Kirsch, ruled that the FDA did not arbitrarily reject the plaintiff's pre-market tobacco product application (PMTA).
The plaintiff "manufactured and distributed hundreds of flavors of e-cigarette liquid." In September 2021, they submitted a PMTA to the defendant in an attempt to bring their products to market. The FDA denied their application, claiming that the plaintiff Gripum did not adequately demonstrate the public health benefits of their product for it to be marketed in accordance with the Family Smoking Prevention and Tobacco Control Act. After being denied by the defendant, the plaintiff requested a court review of the FDA's decision.
According to the Family Smoking Prevention and Tobacco Control Act, companies like the plaintiff seeking to sell new tobacco products must obtain approval before they can be marketed. If the Secretary of Health and Human Services determines that the product is not appropriate for protecting public health (suitability standards), the application may be denied. The suitability standards are determined by the Secretary, taking into account "the risks and benefits to the population as a whole, including users and nonusers of tobacco products.
The FDA explained that they needed "substantial and reliable evidence...about the potential benefits to adult smokers" when rejecting the plaintiff's application. The plaintiff claimed in their appeal that the FDA's denial was arbitrary because they did not express attainable standards before rejecting the application, allegedly changed evidence standards, and did not take a personalized approach to the application, applying a universal presumption instead.
The Seventh Circuit Court ruled that the FDA acted in accordance with the principles of the law when evaluating the plaintiff's application. They determined that the standards used by the defendant were directly derived from the law, meaning further elaboration may not be necessary. Judges Wood, Hamilton, and Kirsch also affirmed that the FDA was consistent in requiring the plaintiff and other companies to provide standards and evidence types. They also rejected the FDA's broad presumption, stating that this argument was based on a "questionable interpretation of the agency's marketing refusal order and statutory burdens.
On Monday, the Seventh Circuit Court ruled that the FDA's denial of an application was not arbitrary or unreasonable and subsequently denied Gripum's request for a review. Gripum was represented in the lawsuit by the law firm Troutman.
Statement
This article's content is compiled from third-party information and is only intended for industry-related communication and learning.
This article does not reflect the views of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only intended for industry exchanges and research.
Due to limitations in the compiling ability, the translated article may not fully reflect the original author's intended meaning. Therefore, please refer to the original article for accuracy.
For any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions, 2FIRSTS maintains complete consistency with the Chinese government.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
